When humans need hydration
The source is poisoned
In whatever form
There is no better way
To poison that
Which is taken for granted
To be safe
With a slow motion for symptoms to develop
And none the wiser
The source is poisoned
In whatever form
There is no better way
To poison that
Which is taken for granted
To be safe
With a slow motion for symptoms to develop
And none the wiser
Recent AZN News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/09/2026 05:01:44 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/02/2026 01:27:28 PM
- IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer • Business Wire • 04/02/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/01/2026 02:30:32 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/31/2026 11:48:12 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/27/2026 12:04:57 PM
- Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD • Business Wire • 03/27/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/20/2026 11:59:41 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 11:51:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/16/2026 12:45:34 PM
- AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer • Business Wire • 03/10/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/10/2026 12:07:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/10/2026 11:37:46 AM
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer • Business Wire • 03/09/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2026 01:11:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2026 12:50:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2026 12:43:30 PM
- Form 8-A12B - Registration of securities [Section 12(b)] • Edgar (US Regulatory) • 03/03/2026 09:01:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/02/2026 09:05:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/02/2026 05:00:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2026 01:59:56 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/25/2026 03:40:05 PM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 02/25/2026 01:30:56 PM
- Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). • Edgar (US Regulatory) • 02/24/2026 09:20:12 PM


